PHASE II TRIAL OF THE mTOR INHIBITOR EVEROLIMUS IN RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL)
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Cutaneous T cell lymphoma
- Focus Therapeutic Use
- 24 Apr 2016 Status changed from recruiting to discontinued due to Poor enrolment.
- 22 Jul 2014 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov.
- 16 Jul 2012 New trial record